Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | PNMT | P11086 | 2/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120626 | 0.85 | GABRA1 (0.40) | HTR2AHTR2CHTR2BCHRNA7NOS3 | |
| SCHEMBL2737265 | 0.79 | NOS3 (0.53) | CHRNA7LOXL2NOS3NOS1NOS2 | |
| SCHEMBL17000207 | 0.78 | SMARCA2 (0.39) | CHRNA7 | |
| SCHEMBL23843301 | 0.77 | NR3C2 (0.34) | NR3C2 | |
| SCHEMBL3507840 | 0.77 | LOXL2 (0.52) | CHRNA7LOXL2NOS3NOS1NOS2 | |
| SCHEMBL5102672 | 0.77 | RECQL (0.52) | CHRNA7LOXL2NOS3NOS1NOS2 | |
| SCHEMBL22844051 | 0.76 | NR3C2 (0.43) | HTR2AHTR2CHTR2BCHRNA7LOXL2 | |
| SCHEMBL19227962 | 0.76 | NR3C2 (0.56) | HTR2AHTR2CHTR2BNR3C2 | |
| SCHEMBL13069319 | 0.76 | NOS2 (0.37) | CHRNA7NOS3NOS1NOS2 | |
| SCHEMBL22639289 | 0.75 | ESR1 (0.36) | NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | HTR2A 2117/4885HTR2C 1224/4885HTR2B 1586/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | HTR2A 2117/4885HTR2C 1224/4885HTR2B 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.